Dyne Therapeutics (DYN) Depreciation & Amortization (CF) (2019 - 2026)
Dyne Therapeutics (DYN) recorded quarterly Depreciation & Amortization (CF) of $600000.0 in Q1 2026, up 27.12% quarter-over-quarter from $472000.0 in Q4 2025, and up 19.52% on a YoY basis from $502000.0 in Q1 2025.
Dyne Therapeutics (DYN) Depreciation & Amortization (CF) (2019 - 2026) Analysis & Trends
Dyne Therapeutics' Depreciation & Amortization (CF) history runs 8 years deep, the most recent figure standing at $600000.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) rose 19.52% year-over-year to $600000.0; the TTM figure through Mar 2026 stood at $2.1 million (up 18.26% YoY), while the FY2025 annual figure was $2.0 million, up 19.55% from the prior year.
- Depreciation & Amortization (CF) was $600000.0 for Q1 2026 at Dyne Therapeutics, up from $472000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $600000.0 in Q1 2026 to a low of $383000.0 in Q4 2022.
- Historically, Depreciation & Amortization (CF) has averaged $443000.0 across 5 years, with a median of $400000.0 in 2022.
- The sharpest annual moves came in 2022 and 2023: Depreciation & Amortization (CF) soared 150.0% in 2022, then declined 20.0% in 2023.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $383000.0 in 2022, then climbed by 4.18% to $399000.0 in 2023, then gained by 12.78% to $450000.0 in 2024, then increased by 4.89% to $472000.0 in 2025, then rose by 27.12% to $600000.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $600000.0 (Q1 2026), $472000.0 (Q4 2025), and $500000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | 1,395.22 |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | 429,663.65 |
| 10 | Dyne Therapeutics | 3.00 Bn | 3.00 Bn | - | 600,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 600,000.00 |
| Mar 31, 2026 | 600,000.00 |
| Dec 31, 2025 | 472,000.00 |
| Dec 31, 2025 | 472,000.00 |
| Sep 30, 2025 | 500,000.00 |
| Sep 30, 2025 | 500,000.00 |
| Jun 30, 2025 | 500,000.00 |
| Jun 30, 2025 | 500,000.00 |
| Mar 31, 2025 | 502,000.00 |
| Mar 31, 2025 | 502,000.00 |
| Dec 31, 2024 | 450,000.00 |
| Dec 31, 2024 | 450,000.00 |
| Sep 30, 2024 | 400,000.00 |
| Sep 30, 2024 | 400,000.00 |
| Jun 30, 2024 | 400,000.00 |
| Jun 30, 2024 | 400,000.00 |
| Mar 31, 2024 | 400,000.00 |
| Mar 31, 2024 | 400,000.00 |
| Dec 31, 2023 | 399,000.00 |
| Dec 31, 2023 | 399,000.00 |